Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug.
Nonsteroidal anti-inflammatory drugs (NSAIDs) induced formation of intestinal ulcers as side effects, in which an unbalanced increase in the number of gram-negative bacteria in the small intestine plays an important role. To clarify how intestinal microflora are influenced by NSAIDs, we examined the effects of 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl) thiophene (BFMeT), an NSAID, on intestinal motility and on the growth of Escherichia coli and Lactobacillus acidophilus. Transit index, a marker of peristalsis, was not different in BFMeT-treated and solvent-treated rats, indicating that BFMeT increased the number of gram-negative bacteria without suppression of peristalsis. The factors that affect the growth of intestinal bacteria were not found in intestinal contents of BFMeT-treated rats, because the growth of E. coli and that of L. acidophilus in the supernatants of small intestinal contents of BFMeT-treated rats and solvent-treated rats were not different. The mechanism of the increase in the number of gram-negative bacteria is still unclear, but heat-killed E. coli cells and their purified lipopolysaccharide (LPS) caused deterioration of BFMeT-induced ileal ulcers, while they could not cause the ulcers by themselves without the NSAID. Concentration of LPS and myeloperoxidase activity level were elevated correlatively in the intestinal mucosa of rats treated with LPS and BFMeT. These results suggest that an increase in the number of gram-negative bacteria and their LPS in the mucosa induces activation of neutrophils together with the help of NSAID action and causes ulcer formation.
Department of Molecular Bacteriology, Graduate School of Medicine, The University of Tokushima, Tokushima, Japan.
Mari
M
Hagiwara
Keiko
K
Kataoka
Hideki
H
Arimochi
Tomomi
T
Kuwahara
Yoshinari
Y
Ohnishi
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development* / Q000472:pathogenicity; D007077:Ileal Diseases / Q000209:etiology*; D007779:Lactobacillus acidophilus / Q000187:drug effects / Q000254:growth & development; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013876:Thiophenes / Q000633:toxicity; D014456:Ulcer / Q000209:etiology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008070:Lipopolysaccharides; D013876:Thiophenes; C064874:DuP 697; D009195:Peroxidase